Want to see ALEC full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.22Last Year’s EPS
-0.3Same Quarter Last Year
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call presented several positive developments, including strong financial health, upcoming trial data, and completion of enrollment for a key program. However, significant challenges remain, such as regulatory hurdles and the complexity of diagnosing and treating FTD. The balance of promising advancements and existing challenges suggests a cautiously optimistic outlook.Company Guidance
Upcoming INFRONT-3 Trial Data
Alector is anticipating top-line data from their Phase III INFRONT-3 trial of latozinemab by mid-Q4 2025. This trial is pivotal as it targets frontotemporal dementia due to the GRN gene mutation, a rare form of dementia with no approved therapy.
Strong Financial Position
The company closed the quarter with $307.3 million in cash, expected to provide runway into the second half of 2027. This financial strength supports their strategic objectives.
Completion of AL101 Phase II Enrollment
The enrollment for the Phase II trial of AL101 in early Alzheimer's disease was completed in April, with trial completion expected in 2026. AL101 aims to elevate progranulin levels, similar to latozinemab, for more prevalent neurodegenerative diseases.
Progranulin Elevation as a Key Endpoint
The FDA has recommended including plasma progranulin as a co-primary endpoint in the INFRONT-3 trial, highlighting its importance as a biologically meaningful marker in FTD-GRN.
ALEC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALEC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $2.44 | $2.10 | -13.93% |
Feb 25, 2026 | $2.39 | $2.56 | +7.11% |
Nov 06, 2025 | $1.30 | $1.28 | -1.54% |
Aug 07, 2025 | $1.46 | $2.15 | +47.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alector (ALEC) report earnings?
Alector (ALEC) is schdueled to report earning on Jul 30, 2026, TBA (Confirmed).
What is Alector (ALEC) earnings time?
Alector (ALEC) earnings time is at Jul 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALEC EPS forecast?
ALEC EPS forecast for the fiscal quarter 2026 (Q2) is -0.22.